TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteer between 6 - 35 months old; Term birth; Birth weight \>2500g;~* Proven legal identity;~* Written consent of the guardian(s) of the volunteer;~Exclusion Criteria:~* Received seasonal influenza vaccine in the current year;~* Suffering from seasonal influenza in the past 6 moths;~* Axillaty temperature \> 37.0 °C;~* History of allergy to any vaccine or vaccine ingredient;~* History of serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, abdominal pain, etc;~* Autoimmune disease or immunodeficiency;~* Congenital malformation, developmental disorders;~* Severe malnutrition;~* Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders;~* History of epilepsy (except febrile seizures occurred \< 2 years of age or pure epilepsy occurred within the past 3 years that does not need treatment)~* Chronic diseases (e.g., viral hepatitis, tuberculosis, diabetes, blood diseases, or neurological disorders)~* Acute disease or acute stage of chronic disease;~* Receipt of any of the following products:~  1. Any subunit vaccine or inactivated vaccine (e.g., pneumococcal vaccine) or treatment of allergy within 14 days prior to study entry;~ 2. Any live attenuated vaccine within 30 days prior to study entry;~ 3. Any other investigational medicine(s) or vaccine within 30 days prior to study entry;~ 4. Blood product within 3 months prior to study entry;~ 5. Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) within 6 month prior to study entry;~* Participate or will participate in other clinical trial(s) during this study;~* Based on the judgment of investigator(s) or the Ethic Committee, there was any condition indicating that the subject should be excluded;

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 35 Months
- Healthy Volunteers: t

Study Arms:
- Experimental group-phase Ⅰ (Type: EXPERIMENTAL): Quadrivalent influenza vaccine
- Experimental group-phase Ⅲ (Type: EXPERIMENTAL): Quadrivalent influenza vaccine
- Control group 1-phase Ⅲ (Type: ACTIVE_COMPARATOR): Trivalent influenza vaccine (contains B/Victoria strain)
- Control group 2-phase Ⅲ (Type: ACTIVE_COMPARATOR): Trivalent influenza vaccine (contains B/Yamagata strain)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of A3309 in Patients With Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients meet protocol specified criteria for dyslipidemia and has successfully completed study requirements with no clinically relevant findings~Exclusion Criteria:~* Medical history or medical condition that would not make the patient a good candidate for the study or would limit the patient´s capability to complete the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A3309 low dose (Type: EXPERIMENTAL): None
- A3309 high dose (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Meet Parkinson's Disease (PD) diagnosis consistent with UK PD diagnostic criteria~* Meet Hoehn and Yahr PD stage~* Good response to levodopa~* Stable regimen of anti-parkinson medications~* Are able to complete a Parkinson's disease diary~* If of childbearing potential(male and female), use an acceptable method of birth control~* Able and willing to sign an IRB/IEC approved informed consent~* Able and willing to understand study requirements, follow study instructions, attend all visits and undergo all planned tests.~Exclusion Criteria:~* Secondary or atypical Parkinson's~* Neurosurgical intervention for Parkinson's disease~* Treatment with apomorphine~* Treatment with anti-psychotic drugs~* Other abnormal findings on physical or neuro exam or history that in the opinion of the investigator would make subject unsuitable for the study or prejudice safety and efficacy evaluation~* MMSE less than 26~* Subjects with untreated or uncontrolled current episode of major depression~* Receipt of any anti-psychotic drugs greater than 1 month in the past 5 years or any exposure in past year (except for quetiapine at doses \<100mg per day)~* Women pregnant or lactating~* History of hepatitis, cholangitis~* Untreated or uncontrolled hypothyroidism or hyperthyroidism~* Drops in blood pressure requiring medication to maintain blood pressure~* Any clinically significant out of range laboratory evaluations~* Known sensitivity to the study medication or its components~* Suicide ideation or type 4 or type 5 on the Columbia suicide severity rating scale~* Finding of malignant melanoma on full body skin exam~* Impulse disorder conditions

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tozadenant (SYN115) 60 mg BID (Type: EXPERIMENTAL): Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
- Tozadenant (SYN115) 120 mg BID (Type: EXPERIMENTAL): Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
- Tozadenant (SYN115) 180 mg BID (Type: EXPERIMENTAL): Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
- Tozadenant (SYN115) 240 mg BID (Type: EXPERIMENTAL): Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
- Sugar Pill (Type: PLACEBO_COMPARATOR): White-coated, modified-oval placebo tablets.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Subjects are eligible for inclusion if they meet the following inclusion criteria:~* Men and women \> 18 years of age~* Written informed consent from the subject~* Stable CAD~* Stable medical condition, will be compliant and able to comply with the requirements of the protocol~Exclusion Criteria:~* Subjects must NOT meet any of the following exclusion criteria:~* Planned CABG~* Hospitalization for acute coronary syndrome if troponin level is \>0.1 ng/mL in the preceding 6 weeks~* Hospitalization for ST-segment acute myocardial infarction (STEMI) in the preceding 12 weeks~* Subjects with chronic inflammatory disease (e.g., RA), inflammatory bowel disease, recent (12 weeks) systemic or localized infection (the latter requiring clinical intervention), or major surgery~* hs-CRP \>15 mg/L repeated on at least 2 occasions \>24 hours apart due to non-cardiovascular systemic inflammatory conditions (e.g., rheumatoid disease)~* Acute or chronic heart failure as defined by the NYHA classification as functional Class III or Class IV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of GERD as defined in this protocol: Heartburn (severity of mild, moderate or severe) 2 or more times in the 7 days prior to the Screening visit (Visit 1) and, on average, at least 2 times per week over the past 3 months.~* Male or female, 18 to 70 years old, inclusive.~* Non-pregnant, non-lactating female patients. Female patients must be postmenopausal, surgically sterile, or using a medically acceptable form of birth control, as determined by the investigator. Females of childbearing potential must agree to continue using an acceptable form of birth control throughout the conduct of the study.~* Negative urine pregnancy test for females of childbearing potential.~* Willingness to adhere to all protocol requirements.~Exclusion Criteria:~* Previous enrollment in the present study.~* Significant clinical illness within 2 weeks prior to the first dose of study medication or a significant illness during the study.~* Use of a PPI, including PRILOSEC OTC®, within 21 days of Screening (Visit 1) or at anytime during the study (Visit 1 through Visit 4).~* Daily therapy with an H2 RA within 14 days of Screening (Visit 1): eg, ranitidine (ZANTAC®), cimetidine (TAGAMET®), nizatidine (AXID®), famotidine (PEPCID®) (occasional use; ie, less than daily, is permitted).~* Use of H2 RAs at any frequency are prohibited throughout the entire study (Visit 1 through Visit 4).~* A history of gastric or esophageal surgery (including, but not limited to, Nissen fundoplication and bariatric surgery), except for simple closure of a perforated ulcer or procedures that would not affect the study as determined by the Clinical Study Team physician at AstraZeneca.~* Clinically significant gastrointestinal (GI) bleeding (eg, melena, frank hematochezia) within 3 days of Screening (Visit 1) or noted at the time of baseline EGD.~* Non-acid related etiologies of esophagitis (eg, pill-induced, caustic ingestion or eosinophilic esophagitis).~Generalized bleeding disorders resulting from hemorrhagic diathesis (such as abnormalities in clotting factors or platelets).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis DS or DS mosaicism by karyotype or chromosomal analysis~* Diagnosis of myelodysplastic syndromes (MDS) with \< 30% blasts or acute myeloid leukemia (AML)~  * Newly diagnosed disease~* Patients with a history of transient myeloproliferative disorder (TMD) are eligible provided the patient is diagnosed with AML or MDS at \> 90 days of age AND meets either of the following criteria:~  * At least 30% blasts in the bone marrow regardless of time since resolution of TMD~ * More than 8 weeks since resolution of TMD with ≥ 5% blasts in the bone marrow~* Immunophenotype required for study entry~* No promyelocytic leukemia~* Shortening fraction ≥ 27% by echocardiogram OR ejection fraction ≥ 50% by radionuclide angiogram~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* AST or ALT \< 2.5 times ULN~* Creatinine adjusted according to age as follows:~  * No greater than 0.4 mg/dL (≤ 5 months)~ * No greater than 0.5 mg/dL (6 months -11 months)~ * No greater than 0.6 mg/dL (1 year-23 months)~ * No greater than 0.8 mg/dL (2 years-5 years)~ * No greater than 1.0 mg/dL (6 years-9 years)~ * No greater than 1.2 mg/dL (10 years-12 years)~ * No greater than 1.4 mg/dL (13 years and over \[female\])~ * No greater than 1.5 mg/dL (13 years to 15 years \[male\])~ * No greater than 1.7 mg/dL (16 years and over \[male\])~* Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min~* No evidence of dyspnea at rest~* No exercise intolerance~* Pulse oximetry \> 94%~* No prior chemotherapy, radiotherapy, or any antileukemic therapy~  * Intrathecal cytarabine therapy given at diagnosis allowed~* Prior therapy for TMD allowed

- Gender: ALL
- Minimum Age: None
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (combination chemotherapy) (Type: EXPERIMENTAL): INDUCTION THERAPY COURSE I: Patients receive cytarabine IT on day 1 and cytarabine IV continuously over 96 hours, daunorubicin hydrochloride IV continuously, and oral thioguanine BID on days 1-4. COURSE II: Patients receive high-dose cytarabine IV over 3 hours BID on days 1, 2, 8, and 9 and asparaginase (IM) on days 2 and 9.~COURSE III: Patients receive treatment as in course I. COURSE IV: Patients receive cytarabine IV, daunorubicin hydrochloride IV, and oral thioguanine as in course I~INTENSIFICATION THERAPY: Patients receive cytarabine IV continuously over 168 hours on days 1-7 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~* Symptomatic CSU patients with CSU diagnosis for at least 6 months.~* Patients must have been on an approved dose of an H1AH for CSU for at least the 3 consecutive days immediately prior to the Day -14 screening visit~* Patients must have documented current use on the day of the initial screening visit~Main Exclusion Criteria~* Clearly defined underlying etiology for chronic urticarias other than CSU (main manifestation being physical urticaria)~* Other skin disease associated with itch Urticarial vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary or acquired angioedema, lymphoma, leukemia, or generalized cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Omalizumab 300mg (Type: EXPERIMENTAL): patients received a dose of omalizumab 300 mg which consisted of two injections of omalizumab 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
- Omalizumab 150mg (Type: EXPERIMENTAL): patients received a dose of omalizumab 150 mg which consisted of one injection of omalizumab 150 mg vial and one injection of placebo 150 mg vial every 4 weeks (Day 1, Week 4 and Week 8)
- Placebo (Type: PLACEBO_COMPARATOR): patients received placebo which consisted of two injections of placebo 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients with relapsing/refractory T-NK/NK lymphoma:~* Ages 18 years and above~* Patients must have a diagnosis of NK-cell (or T-NK) non-Hodgkin's lymphoma, nasal or nasal-type.~* Stage I, II, III, or IV disease~* Creatinine less than 3 x upper limit of normal (ULN)~* Able to give informed consent~* No prior treatment with asparaginase~Patients with T-NK/NK lymphoma (de novo patients ):~* Ages 18 years and above~* Patients must have a diagnosis of NK-cell (or T-NK) non-Hodgkin's lymphoma, nasal or nasal-type.~* Stage I, II, III, or IV disease~* Creatinine less than 3 x upper limit of normal (ULN)~* Able to give informed consent~* no prior chemotherapy or radiotherapy~Exclusion Criteria:~* Patients who are pregnant or nursing~* Any factor which might limit the patient's ability to provide informed consent~* Liver insufficiency~* Evolutive thrombosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have given written informed consent and be able to comply with all study requirements.~* Males or females aged 18-75, inclusive, at the time of Informed Consent.~* Females must be non-pregnant and non-lactating, and either surgically sterile or post- menopausal.~* Males must be surgically sterile, abstinent or using an acceptable contraceptive method.~* Body mass index (BMI) ≥ 27.0 - ≤ 39.0 kilograms per square meter (kg/m\^2).~* Diagnosis of Type 2 Diabetes Mellitus with an Hemoglobin A1C (HbA1c) ≥7.3% and ≤9.5% at screening.~* Must have been on a stable dose of Oral Antidiabetic Therapy for a minimum of 3 months prior to Screening.~* ≥ 10% liver fat prior to randomization assessed by MRI-PDFF.~* Stable body weight for at least 3 months before screening.~Exclusion Criteria:~* Clinically-significant abnormalities in medical history or physical examination.~* Clinically-significant abnormalities in screening laboratory values that would render a participant unsuitable for inclusion, per Sponsor.~* Evidence of uncorrected hypothyroidism or hyperthyroidism results at Screening.~* History of solid organ transplantation or renal dialysis.~* Clinically-significant complications of diabetes.~* Treatment with another Study Drug, biological agent, or device within one-month of screening.~* Known history or evidence of liver disease with a positive test for human immunodeficiency virus (HIV), Hepatitis C virus (HCV), or chronic Hepatitis B virus (HBV), or chronic liver disease other than NASH.~* Recent history of, or current drug or alcohol abuse.~* Current use of concomitant medications known to significantly impact body weight or that may cause liver toxicity, per Investigator~* Use of anticoagulant/Antiplatelet agents unless the dose has been stable for 4 weeks prior to the first dose of study drug\]~* Use of non-steroidal anti-inflammatory drug nimesulide or any other drug influencing coagulation (except lose-dose aspirin).~* Use of obeticholic acid or ursodeoxycholic acid~* Considered unsuitable for inclusion by the Principal Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IONIS DGAT2Rx (Type: EXPERIMENTAL): Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks
- Placebo (sterile saline 0.9) (Type: PLACEBO_COMPARATOR): Calculated volume to match active comparator administered subcutaneously once weekly for 13 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Telavancin in Normal and Obese Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult subjects, 18 to 50 years~* Nonsmokers within the last 1 year~* Weight \> 110 lbs~Exclusion Criteria:~* History of significant hypersensitivity reaction or intolerance to telavancin~* Aspartate or alanine aminotransferase \> 1.5 times the upper limit of normal~* Estimated creatinine clearance \<60 mL/minute and serum creatinine \>1.5 mg/dL~* Female subjects who are pregnant or breast feeding~* History of alcohol or substance abuse or dependence within the last 1 year~* Use of prescription or nonprescription drugs (unless hormonal contraceptives) within 7 to 14 days prior to telavancin administration~* Participation in a clinical trials within last 30 days~* Donated blood (\>500 mL) within the last 56 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Telavancin Administration (Type: EXPERIMENTAL): Single dose of telavancin administered as a 1-hour intravenous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete